Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.

Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, Yazdany J.

JAMA. 2011 Feb 2;305(5):480-6. doi: 10.1001/jama.2011.67.

2.

Relationships between driving distance, rheumatoid arthritis diagnosis, and disease-modifying antirheumatic drug receipt.

Polinski JM, Brookhart MA, Ayanian JZ, Katz JN, Kim SC, Lii J, Tonner C, Yelin E, Solomon DH.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1634-43. doi: 10.1002/acr.22333.

3.

Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey.

Solomon DH, Yelin E, Katz JN, Lu B, Shaykevich T, Ayanian JZ.

Arthritis Res Ther. 2013 Mar 18;15(2):R43. doi: 10.1186/ar4201.

4.

Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.

Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF.

J Manag Care Spec Pharm. 2014 Nov;20(11):1110-20.

5.

Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.

Bonafede MM, Fox KM, Johnson BH, Watson C, Gandra SR.

Clin Ther. 2012 Feb;34(2):457-67. doi: 10.1016/j.clinthera.2011.12.016. Epub 2012 Jan 28.

PMID:
22284901
6.

Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.

Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, Levin R, Solomon DH.

Arthritis Rheum. 2007 Aug 15;57(6):928-34.

7.

Receipt of high risk medications among elderly enrollees in Medicare Advantage plans.

Qato DM, Trivedi AN.

J Gen Intern Med. 2013 Apr;28(4):546-53. doi: 10.1007/s11606-012-2244-9. Epub 2012 Nov 6.

8.

Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.

Yazdany J, Tonner C, Schmajuk G, Lin GA, Trivedi AN.

Arthritis Care Res (Hoboken). 2014 Oct;66(10):1447-55. doi: 10.1002/acr.22312.

9.
10.

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.

Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S.

JAMA. 2011 Jun 22;305(24):2525-31. doi: 10.1001/jama.2011.878.

PMID:
21693740
11.

Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.

Shafrin J, Ganguli A, Gonzalez YS, Shim JJ, Seabury SA.

J Manag Care Spec Pharm. 2016 Dec;22(12):1472-1481.

13.

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.

Griffiths RI, Bar-Din M, MacLean C, Sullivan EM, Herbert RJ, Yelin EH.

Ther Apher. 2001 Apr;5(2):92-104.

PMID:
11354305
14.

Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey.

Solomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):184-9. doi: 10.1002/acr.20674.

15.

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.

Jin Y, Desai RJ, Liu J, Choi NK, Kim SC.

Arthritis Res Ther. 2017 Jul 5;19(1):159. doi: 10.1186/s13075-017-1366-1.

16.

Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients.

Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB.

Arthritis Care Res (Hoboken). 2013 Feb;65(2):299-303. doi: 10.1002/acr.21798.

17.

Relationship between quality of care and racial disparities in Medicare health plans.

Trivedi AN, Zaslavsky AM, Schneider EC, Ayanian JZ.

JAMA. 2006 Oct 25;296(16):1998-2004.

PMID:
17062863
18.

Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.

Kim SC, Yelin E, Tonner C, Solomon DH.

Arthritis Care Res (Hoboken). 2013 Sep;65(9):1529-33. doi: 10.1002/acr.21997.

19.

Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug.

Martin RW, McCallops K, Head AJ, Eggebeen AT, Birmingham JD, Tellinghuisen DJ.

BMC Med Inform Decis Mak. 2013 Aug 12;13:89. doi: 10.1186/1472-6947-13-89.

20.

Quality of care in for-profit and not-for-profit health plans enrolling Medicare beneficiaries.

Schneider EC, Zaslavsky AM, Epstein AM.

Am J Med. 2005 Dec;118(12):1392-400.

PMID:
16378784

Supplemental Content

Support Center